Downstream Processing Featured Articles
-
Single-Use Standardization: Is It Holding Back The Biopharma Industry?
6/1/2015
The data from BioPlan Associates’ 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production speaks to the industry’s ongoing desires for standardization in single-use devices. As usage of these disposable devices increases, the gap between the importance of standardization and end-users’ satisfaction with their supplier’s standardization efforts has steadily been worsening.
-
Alzheimer’s Disease In Mice Alleviated Promising Therapeutic Approach For Humans
11/25/2012
Alzheimer’s disease is one of the most common causes of dementia. In Germany and Switzerland alone, around 1.5 million people are affected, and forecasts predict a doubling of the number of patients worldwide within the next 20 years.
-
Getting A Biotech Back On The Path Toward Commercialization
3/28/2012
There has been much debate as to how much it costs to get a new drug from discovery to market — anywhere from Light and Waburton’s 2011 estimate of R&D costs being in the neighborhood of $59.4M to PhRMA’s mind-numbing figure of $1.32B. By Rob Wright
-
Therapure Announces Opening Of Custom Biologics Manufacturing Wing
4/20/2012
Recently marked the official opening of Therapure Biopharma Inc.’s Custom Biologics Manufacturing Wing, which supports the development and manufacture of innovative medical treatments.
-
RNA-Based Therapy Brings New Hope For An Incurable Blood Cancer
10/10/2012
Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and Lymphoma Society, this disease is devastating, and new therapies are sorely needed.
-
Is There An Enzyme In Your Future?
8/25/1998
A method for reducing the chemical steps in vitamin C synthesis from six to two underscores the growing importance of enzymes in organic synthesis...
-
Major Cancer Protein Amplifies Global Gene Expression, NIH Study Finds
9/27/2012
Scientists may have discovered why a protein called MYC can provoke a variety of cancers. Like many proteins associated with cancer, MYC helps regulate cell growth.
-
Biosimilars In Emerging Markets
7/1/2013
To date, 14 biosimilar marketing authorizations have been granted in the EU. Despite their lower cost (20% to 35% less than branded counterparts), the uptake and use of biosimilars in the EU has been less than expected. However, the ongoing global economic downturn, skyrocketing healthcare costs, and patent expiry by 2018 of biologics with annual sales in excess of $67 billion have prompted a renewed global interest in biosimilars, especially in emerging markets.
-
Mayo Clinic Uses New Approach To Reverse Multiple Sclerosis In Mice Models
6/28/2012
Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published today in the journal PLoS ONE, suggests new possible therapies for MS patients.
-
Researchers Discover Blood Biomarker For Lou Gehrig's Disease, Could Lead To New Treatments
8/6/2012
Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease.